Every material Form 8-K Cytokinetics filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cytokinetics said its Chief Accounting Officer, Robert Wong, will leave the company effective December 31, 2024, and that there is no disagreement with him on financial condition or reporting. Chief Financial Officer Sung Lee, who joined in May 2024, will also take on the role of principal accounting officer when Wong departs, so the change is administrative and does not add a new executive.
Robert Wong, Chief Accounting Officer and principal accounting officer, departs effective December 31, 2024
Sung Lee, CFO since May 2024, will additionally serve as principal accounting officer upon Wong's departure
Filing states no disagreement between Wong and the company on financial condition or financial reporting
Cytokinetics granted Bayer Consumer Care AG an exclusive license to develop and commercialize aficamten in Japan under an agreement signed November 18, 2024. Cytokinetics will receive a €50 million upfront payment, with additional milestone and royalty payments possible, while it keeps the right to run certain clinical trials in Japan.
Upfront payment of €50 million from Bayer
Milestone payments of up to €90 million tied to clinical and launch events in hypertrophic cardiomyopathy
Commercial milestones of up to €490 million plus tiered royalties on Japan net sales, from the high teens to the low thirties percent
Agreement dated November 18, 2024; full text to be filed with the 2024 Form 10-K
Cytokinetics said director Santo J. Costa resigned from its Board of Directors with immediate effect, notice given November 1, 2024. The company said the resignation was for personal reasons and not due to any disagreement with the company, and the board was reduced from nine to eight directors.
Santo J. Costa resigned from the Board of Directors effective immediately; notice was given November 1, 2024.
The company said the resignation was for personal reasons, not a disagreement on operations, policies, or practices.
Board size was reduced from nine to eight directors.
Cytokinetics hired Brett Pletcher as Executive Vice President, Chief Legal Officer, effective August 19, 2024, under an offer letter dated August 13, 2024. The filing sets his $560,000 base salary and a 45% target bonus, along with sign-on and initial equity awards, which are routine terms for a senior executive hire.
Start date is August 19, 2024; base salary is $560,000
Target bonus is 45% of base salary; signing bonus is $100,000
Initial equity awards include RSUs and options each valued at $1,891,620, and PSUs valued at $833,520 at target
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cytokinetics filing is on SEC EDGAR ↗. 8-K briefs of other companies →